Knockdown of SLC1A5 increased the sensitivity of luminal breast cancer cells to tamoxifen treatment, possibly by modulating the expression of the pentose phosphate pathway enzyme TALDO1, which is crucial for cancer cell growth and proliferation. Here, SLC1A5 is linked to breast cancer.